Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2001 Nov;71(5):589–595. doi: 10.1136/jnnp.71.5.589

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

K Rockwood 1, J Mintzer 1, L Truyen 1, T Wessel 1, D Wilkinson 1
PMCID: PMC1737604  PMID: 11606667

Abstract

OBJECTIVE—To assess the efficacy and safety of galantamine in Alzheimer's disease at 3 months using flexible dose escalation.
METHODS—A randomised, double blind, placebo controlled trial in 43 centres in the United States, Canada, Great Britain, South Africa, Australia, and New Zealand. Patients with probable Alzheimer's disease (n=386; 171 women) with a score of 11-24 on the mini mental state examination, and a score⩾12 on the cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog) were randomised to placebo, or galantamine escalated over 4 weeks to a maintenance dose of 24 or 32 mg/day. The primary outcome measures were the change in ADAS-cog score and the clinician's interview based impression of change plus caregiver input (CIBIC-plus) score. Activities of daily living (ADL) and behavioural symptoms were secondary outcomes. To compare the effects of highest levels of dosing, an observed cases (OC) analysis was undertaken, with classic intention to treat (ITT) and ITT with last observation carried forward (LOCF) as confirmatory analyses.
RESULTS—At 3 months, galantamine (24-32 mg/day) produced a significantly better outcome on cognitive function than placebo (treatment difference=1.9 points on ADAS-cog, p=0.002) and a significantly better global response than placebo, as measured by CIBIC-plus (deterioration in 21% of patients on galantamine v 37% on placebo; p<0.001). Galantamine produced significant benefits on basic and instrumental ADL. Behavioural symptoms did not change significantly from baseline levels in either group. Adverse events (primarily gastrointestinal) were of mild to moderate intensity. There were no important differences between the OC, ITT, and ITT/LOCF analyses. Most patients (82%) who were maintained on the higher dose of galantamine completed the study.
CONCLUSIONS—Patients on galantamine, compared with those on placebo, experienced benefits in cognitive function and instrumental and basic activities of daily living. Flexible dose escalation of galantamine was well tolerated.



Full Text

The Full Text of this article is available as a PDF (212.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albuquerque E. X., Alkondon M., Pereira E. F., Castro N. G., Schrattenholz A., Barbosa C. T., Bonfante-Cabarcas R., Aracava Y., Eisenberg H. M., Maelicke A. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther. 1997 Mar;280(3):1117–1136. [PubMed] [Google Scholar]
  2. Antuono P. G. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. Arch Intern Med. 1995 Sep 11;155(16):1766–1772. [PubMed] [Google Scholar]
  3. Barclay L. L., Zemcov A., Blass J. P., Sansone J. Survival in Alzheimer's disease and vascular dementias. Neurology. 1985 Jun;35(6):834–840. doi: 10.1212/wnl.35.6.834. [DOI] [PubMed] [Google Scholar]
  4. Bartus R. T., Dean R. L., 3rd, Beer B., Lippa A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982 Jul 30;217(4558):408–414. doi: 10.1126/science.7046051. [DOI] [PubMed] [Google Scholar]
  5. Begg C., Cho M., Eastwood S., Horton R., Moher D., Olkin I., Pitkin R., Rennie D., Schulz K. F., Simel D. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996 Aug 28;276(8):637–639. doi: 10.1001/jama.276.8.637. [DOI] [PubMed] [Google Scholar]
  6. Bentham P., Gray R., Sellwood E., Raftery J. Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished. BMJ. 1999 Sep 4;319(7210):640–641. doi: 10.1136/bmj.319.7210.640a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bores G. M., Huger F. P., Petko W., Mutlib A. E., Camacho F., Rush D. K., Selk D. E., Wolf V., Kosley R. W., Jr, Davis L. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther. 1996 May;277(2):728–738. [PubMed] [Google Scholar]
  8. Burns A., Rossor M., Hecker J., Gauthier S., Petit H., Möller H. J., Rogers S. L., Friedhoff L. T. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord. 1999 May-Jun;10(3):237–244. doi: 10.1159/000017126. [DOI] [PubMed] [Google Scholar]
  9. Buysse D. J., Reynolds C. F., 3rd, Monk T. H., Berman S. R., Kupfer D. J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193–213. doi: 10.1016/0165-1781(89)90047-4. [DOI] [PubMed] [Google Scholar]
  10. Cummings J. L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D. A., Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308–2314. doi: 10.1212/wnl.44.12.2308. [DOI] [PubMed] [Google Scholar]
  11. Farlow M. R., Evans R. M. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology. 1998 Jul;51(1 Suppl 1):S36–S67. doi: 10.1212/wnl.51.1_suppl_1.s36. [DOI] [PubMed] [Google Scholar]
  12. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  13. Francis P. T., Palmer A. M., Snape M., Wilcock G. K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137–147. doi: 10.1136/jnnp.66.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gélinas I., Gauthier L., McIntyre M., Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999 Sep-Oct;53(5):471–481. doi: 10.5014/ajot.53.5.471. [DOI] [PubMed] [Google Scholar]
  15. Knapp M. J., Knopman D. S., Solomon P. R., Pendlebury W. W., Davis C. S., Gracon S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 1994 Apr 6;271(13):985–991. [PubMed] [Google Scholar]
  16. Levin E. D., Simon B. B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998 Aug;138(3-4):217–230. doi: 10.1007/s002130050667. [DOI] [PubMed] [Google Scholar]
  17. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  18. Mohs R. C., Knopman D., Petersen R. C., Ferris S. H., Ernesto C., Grundman M., Sano M., Bieliauskas L., Geldmacher D., Clark C. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 (Suppl 2):S13–S21. [PubMed] [Google Scholar]
  19. Morris J. C., Cyrus P. A., Orazem J., Mas J., Bieber F., Ruzicka B. B., Gulanski B. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology. 1998 May;50(5):1222–1230. doi: 10.1212/wnl.50.5.1222. [DOI] [PubMed] [Google Scholar]
  20. Newhouse P. A., Potter A., Levin E. D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging. 1997 Sep;11(3):206–228. doi: 10.2165/00002512-199711030-00005. [DOI] [PubMed] [Google Scholar]
  21. Nordberg A., Nilsson-Håkansson L., Adem A., Hardy J., Alafuzoff I., Lai Z., Herrera-Marschitz M., Winblad B. The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. Prog Brain Res. 1989;79:353–362. [PubMed] [Google Scholar]
  22. Nordberg A., Svensson A. L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf. 1998 Dec;19(6):465–480. doi: 10.2165/00002018-199819060-00004. [DOI] [PubMed] [Google Scholar]
  23. Pryse-Phillips W. Do we have drugs for dementia? No. Arch Neurol. 1999 Jun;56(6):735–737. doi: 10.1001/archneur.56.6.735-a. [DOI] [PubMed] [Google Scholar]
  24. Raskind M. A., Cyrus P. A., Ruzicka B. B., Gulanski B. I. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. J Clin Psychiatry. 1999 May;60(5):318–325. doi: 10.4088/jcp.v60n0510. [DOI] [PubMed] [Google Scholar]
  25. Raskind M. A., Peskind E. R., Wessel T., Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000 Jun 27;54(12):2261–2268. doi: 10.1212/wnl.54.12.2261. [DOI] [PubMed] [Google Scholar]
  26. Riter R. N., Fries B. E. Predictors of the placement of cognitively impaired residents on special care units. Gerontologist. 1992 Apr;32(2):184–190. doi: 10.1093/geront/32.2.184. [DOI] [PubMed] [Google Scholar]
  27. Rockwood K., MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology. 2001 May;20(2):51–56. doi: 10.1159/000054761. [DOI] [PubMed] [Google Scholar]
  28. Rockwood K., Stolee P., Howard K., Mallery L. Use of Goal Attainment Scaling to measure treatment effects in an anti-dementia drug trial. Neuroepidemiology. 1996;15(6):330–338. doi: 10.1159/000109923. [DOI] [PubMed] [Google Scholar]
  29. Rogers S. L., Doody R. S., Mohs R. C., Friedhoff L. T. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11;158(9):1021–1031. doi: 10.1001/archinte.158.9.1021. [DOI] [PubMed] [Google Scholar]
  30. Rogers S. L., Farlow M. R., Doody R. S., Mohs R., Friedhoff L. T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan;50(1):136–145. doi: 10.1212/wnl.50.1.136. [DOI] [PubMed] [Google Scholar]
  31. Rogers S. L., Friedhoff L. T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia. 1996 Nov-Dec;7(6):293–303. doi: 10.1159/000106895. [DOI] [PubMed] [Google Scholar]
  32. Rosen W. G., Mohs R. C., Davis K. L. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 Nov;141(11):1356–1364. doi: 10.1176/ajp.141.11.1356. [DOI] [PubMed] [Google Scholar]
  33. Rösler M., Anand R., Cicin-Sain A., Gauthier S., Agid Y., Dal-Bianco P., Stähelin H. B., Hartman R., Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633–638. doi: 10.1136/bmj.318.7184.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Schneider L. S. New therapeutic approaches to Alzheimer's disease. J Clin Psychiatry. 1996;57 (Suppl 14):30–36. [PubMed] [Google Scholar]
  35. Schneider L. S., Olin J. T., Doody R. S., Clark C. M., Morris J. C., Reisberg B., Schmitt F. A., Grundman M., Thomas R. G., Ferris S. H. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 (Suppl 2):S22–S32. doi: 10.1097/00002093-199700112-00004. [DOI] [PubMed] [Google Scholar]
  36. Schrattenholz A., Pereira E. F., Roth U., Weber K. H., Albuquerque E. X., Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol. 1996 Jan;49(1):1–6. [PubMed] [Google Scholar]
  37. Tariot P. N., Solomon P. R., Morris J. C., Kershaw P., Lilienfeld S., Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000 Jun 27;54(12):2269–2276. doi: 10.1212/wnl.54.12.2269. [DOI] [PubMed] [Google Scholar]
  38. Thal L. J., Schwartz G., Sano M., Weiner M., Knopman D., Harrell L., Bodenheimer S., Rossor M., Philpot M., Schor J. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Neurology. 1996 Dec;47(6):1389–1395. doi: 10.1212/wnl.47.6.1389. [DOI] [PubMed] [Google Scholar]
  39. Vasilenko E. T., Tonkopii V. D. Kharakteristika galantamina kak obratimogo ingibitora kholinésterazy. Biokhimiia. 1974 Jul-Aug;39(4):701–703. [PubMed] [Google Scholar]
  40. Watkins P. B., Zimmerman H. J., Knapp M. J., Gracon S. I., Lewis K. W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 1994 Apr 6;271(13):992–998. [PubMed] [Google Scholar]
  41. Whitehouse P. J., Martino A. M., Antuono P. G., Lowenstein P. R., Coyle J. T., Price D. L., Kellar K. J. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 1986 Apr 16;371(1):146–151. doi: 10.1016/0006-8993(86)90819-x. [DOI] [PubMed] [Google Scholar]
  42. Wilcock G. K., Lilienfeld S., Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ. 2000 Dec 9;321(7274):1445–1449. doi: 10.1136/bmj.321.7274.1445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Wolinsky F. D., Callahan C. M., Fitzgerald J. F., Johnson R. J. Changes in functional status and the risks of subsequent nursing home placement and death. J Gerontol. 1993 May;48(3):S94–101. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES